At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 53 enrolled
Drug / intervention
Juvéderm® VOLIFT®™ with Lidocainedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BEAM: Prospective Open Label Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Treatment of Dynamic Radial Cheek Line Skin Depressions
In Brief
A Phase 4 clinical trial evaluating Juvéderm® VOLIFT®™ with Lidocaine for Cheek Line Depressions. Completed, enrolled 53 participants across 1 site.
Detailed Summary
This study will evaluate the effectiveness of Juvéderm® VOLIFT®™ with Lidocaine for dynamic radial cheek line skin depressions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCheek Line Depressions
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedDec 2016
Primary CompletionDec 2016
TodayJul 2026
First PostedDec 2, 2016
Enrollment StartOct 13, 2016
Primary CompletionDec 14, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.6 years ago
Interventions
Juvéderm® VOLIFT®™ with Lidocainedevice
Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.